OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

$1.00-0.02 (-1.96%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OVID Price Action

Last 7 days

-2.9%

Last 30 days

-3.8%

Last 90 days

-13.0%

Trailing 12 Months

-71.4%

OVID RSI Chart

OVID Valuation

Market Cap

71.0M

Price/Earnings (Trailing)

-2.18

Price/Sales (Trailing)

132.61

EV/EBITDA

-1.75

Price/Free Cashflow

-1.23

OVID Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OVID Fundamentals

OVID Revenue

Revenue (TTM)

567.6K

Rev. Growth (Yr)

124.24%

Rev. Growth (Qtr)

4.45%

OVID Earnings

Earnings (TTM)

-32.5M

Earnings Growth (Yr)

-24.46%

Earnings Growth (Qtr)

-264.37%

OVID Profitability

EBT Margin

-5725.94%

Return on Equity

-42.6%

Return on Assets

-31.66%

Free Cashflow Yield

-81.59%

OVID Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

-0.46

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	473.7K	0	0	0
2023	850.6K	198.4K	296.3K	391.7K
2022	167.0M	84.3M	42.9M	1.5M
2021	61.6M	110.5M	159.4M	208.4M
2020	0	0	0	12.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
WEBSITE	ovidrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	40

Ovid therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Ovid therapeutics Inc? What does OVID stand for in stocks?

OVID is the stock ticker symbol of Ovid therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ovid therapeutics Inc (OVID)?

As of Fri Dec 20 2024, market cap of Ovid therapeutics Inc is 71.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers.

Is Ovid therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OVID is over valued or under valued. Whether Ovid therapeutics Inc is cheap or expensive depends on the assumptions which impact Ovid therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OVID.

What is Ovid therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, OVID's PE ratio (Price to Earnings) is -2.18 and Price to Sales (PS) ratio is 132.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OVID PE ratio will change depending on the future growth rate expectations of investors.